Stock option awards were granted to existing executives.

Entry into a Material Definitive Agreement. On April 19, 2026, Modular Medical, Inc. (the “Company”) entered into a Placement Agency Agreement (the “Agreement”) with Maxim Group LLC (the “Placement Agent”), relating to a registered direct offering (the “Offering”) of 750,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), referred to as the “Shares.” The gross proceeds to the Company from the Offering will be approximately $3.375 million, before deductin…

of Form 8-K, the information regarding the Reverse Split (as defined below) contained in

Entry into a Material Definitive Agreement. On March 3, 2026, Modular Medical, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC (the “Placement Agent”) and securities purchase agreements (the “Securities Purchase Agreements”) with multiple investors, relating to a best-efforts offering (the “Offering”) of (i) 62,098,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), (ii) pre-funded wa…

Creation of a Direct Financial Obligation or an Obligation under an Off Balance Sheet Arrangement of the Registrant. The disclosures in

Entry into a Material Definitive Agreement Credit Facility On February 23, 2026, Modular Medical, Inc. (the “Company”) issued a secured promissory note (the “Note”) to James E. Besser (“the Lender”), the Company’s chief executive officer, that provides the Company with a $350,000 revolving credit facility with all amounts being drawn down by the Company thereunder being due and payable, subject to acceleration in the event of a default, on March 25, 2026 (the “Maturity Date”). Interest at the…

of Form 8-K, the information regarding the increase in authorized shares contained in

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on June 30, 2025, Modular Medical, Inc. (the “Company”) received written notice (the “Notice”) from the Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”), for the last 30 consecutive business days, had closed below the minimum $1 per share and, as a result, the Company is not…

Entry into a Material Definitive Agreement. On December 10, 2025, Modular Medical, Inc. (the “Company”) entered into an Underwriting Agreement (the “Agreement”) with Newbridge Securities Corporation (the “Underwriter”), relating to a firm commitment underwritten offering (the “Offering”) of (i) 12,173,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), referred to as the “Firm Shares,” and (ii) accompanying warrants exercisable to purchase up to 6,086,50…

Entry into a Material Definitive Agreement. As previously disclosed, in May 2023, Modular Medical, Inc. (the “Company”) entered into an underwriting agreement with Newbridge Securities Corporation (“Newbridge”) and issued, in connection with an underwritten offering, warrants to purchase 3,564,183 shares of the Company’s common stock (the “2023 Warrants”) with the 2023 Warrants having an exercise price of $1.22 per share. As previously disclosed, in March 2025, the Company issued, in connecti…

Unregistered Sales of Equity Securities. The Company issued the New Warrants in reliance on the exemption provided by Section 3(a)(9) of the Securities Act as involving an exchange by the Company exclusively with its security holders, Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and Rule 506 promulgated thereunder and in reliance on similar exemptions under applicable state laws with such reliance on Rule 506 based in part upon a representation of eac…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 30, 2025, Modular Medical Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock (“Common Stock”) for the 30 consecutive business days ending on June 27, 2025, the Company no longer meets the requirement to maintain a minimum bid price of $1 pe…

Director — Jeffrey Goldberg: Appointment of Jeffrey Goldberg as a non-employee director.

Entry into a Material Definitive Agreement. Private Placement On March 20, 2025, Modular Medical, Inc. (the “Company”) entered into Securities Purchase Agreements (the “Purchase Agreements”) with investors (the “Investors”) for the private placement (the “Private Placement”) of 6,247,656 units (each a “Unit”), with each Unit consisting of (A) two shares of the Company’s common stock, par value $0.001 per share (“Common Stock”) and (B) one warrant (a “Warrant”) to purchase one share of Common…

The Securities being sold pursuant to the Purchase Agreement are being sold and issued without registration under the Securities Act, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and/or Rule 506 promulgated thereunder, and in reliance on similar exemptions under applicable state laws. For the Securities being sold pursuant to the Subscription Agreement, the Company replied upon the exemption from the registrat…

Entry into a Material Definitive Agreement. On November 21, 2024, Modular Medical, Inc. (the “Company”) entered into an Underwriting Agreement (the “Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC (the “Underwriter”), relating to a firm commitment underwritten offering (the “Offering”) of 5,450,573 shares (the “Shares”) of common stock of the Company, par value $0.001 per share (“Common Stock”), at a public offering price of $1.50 per share. The Offerin…

The filing describes a compensatory arrangement and equity grants, not a management change.

Compensation actions and equity grants for executive officers.

Entry into a Material Definitive Agreement. On February 15, 2024, Modular Medical, Inc. (the “Company”) entered into an Underwriting Agreement (the “Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC (the “Underwriter”), relating to a firm commitment underwritten offering (the “Offering”) of 9,090,910 shares (the “Shares”) of common stock of the Company (“Common Stock”). The public offering price is $1.10 per share of Common Stock. Pursuant to the Agreemen…

Other Events. Effective January 29, 2024, the Company suspended, and is not offering any shares of its common stock pursuant to, the prospectus supplement dated November 22, 2023, relating to the Sales Agreement, dated November 22, 2023 (the “ATM Agreement”), by and between the Company and Leerink Partners LLC. The Company will not make any sales of common stock pursuant to the ATM Agreement unless and until a new prospectus supplement is filed with the SEC; however, the Sales Agreement remai…

of Form 8-K, the information regarding the increase in authorized shares contained in

Entry into a Material Definitive Agreement. On November 22, 2023, Modular Medical, Inc. (the “Company”) entered into a Sales Agreement (the “ATM Agreement”) with Leerink Partners LLC (“Leerink”) under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for aggregate gross proceeds of up to $6,500,000 through an “at the market offering” program under which Leerink will act as sale…

The filing describes a new bonus program for employees, not a management change.

Unregistered Sales of Equity Securities. The relevant information in

Unregistered Sales of Equity Securities. The relevant information in